Skip to content

Trans-aortic Valve Replacement and Renal Infarction

Trans-catheter Aortic Valve Replacement and Renal Infarction Among Patients With Severe Aortic Stenosis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03474250
Enrollment
20
Registered
2018-03-22
Start date
2018-04-01
Completion date
2018-12-31
Last updated
2018-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Infarction

Brief summary

Kidney Magnetic Resonance assessment before and after undergoing transcatheter aortic valve replacement

Detailed description

Each patient will undergo Magnetic Resonance assessment of the kidneys before the TAVR. on the third to 7th day after the ATVR, a second MRI to the kidneys will be performed. we will assess the changes and new lesions between both MRI tests and will perform a qualitative and quantitative measurement.

Interventions

DIAGNOSTIC_TESTMagnetic Resonance test for kidney

Magnetic Resonance test for kidney

Sponsors

Sheba Medical Center
Lead SponsorOTHER_GOV

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* Severe symptomatic aortic stenosis * Patient is able to lay down supine for 20 min (the time needed to perform the MRI) without any difficulties.

Exclusion criteria

* Patient is on chronic renal replacement therapy (Dialysis) * Documented Thrombus in the left ventricle or left atria

Design outcomes

Primary

MeasureTime frameDescription
New Renal Infarctionone yearNew low signal intensity lesions on diffusion weighted images on MRI.

Secondary

MeasureTime frameDescription
Hematuriaone yearNew hematuria on urine test.
Elevation in Blood Pressureone yearDelta of more than 5%
Elevation in Plasma Renin Activityone yearDelta of more than 5%
Elevation in Aldosteron levelone yearDelta of more than 5%

Countries

Israel

Contacts

Primary ContactArwa Younis, Doctor
or.younis@gmail.com0544731936

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026